MAS-1新型水包油佐剂/递送系统降低季节性流感疫苗血凝素剂量或可增强老年人抗体应答的效力、持久性和交叉反应性
在65岁及以上老年人中开展1期随机双盲佐剂剂量递增试验,比较含9 µg血凝素(HA)的0.3 mL或0.5 mL MAS-1佐剂三价流感疫苗与高剂量(HD)流感疫苗。0.3 mL MAS-1佐剂组未发现安全性问题且节省HA剂量,0.5 mL组出现迟发性注射部位反应;MAS-1佐剂疫苗诱导更高的HAI抗体应答且持久性延长至接种后至少168天,并增强对部分非疫苗株的交叉反应抗体。
要点
- 0.3 mL MAS-1佐剂可节省HA剂量且无安全性担忧,0.5 mL剂量引起迟发性注射部位反应。
- MAS-1佐剂疫苗增强接种后至少168天的HAI抗体滴度、平均倍数增长和血清转化率。
- MAS-1佐剂疫苗增强对部分非研究疫苗流感病毒的交叉反应抗体。
核心结论
- MAS-1佐剂在0.3 mL剂量下提供HA剂量节省且无安全性担忧,但0.5 mL剂量引起迟发性注射部位反应。
- MAS-1佐剂疫苗诱导更高的HAI抗体应答且持久性延长(包括针对历史毒株),从而在整个流感季节为老年人提供更大的潜在疫苗效力。
研究设计与样本
- 1期随机双盲安全性及免疫原性佐剂剂量递增试验,在65岁及以上人群中开展。
- 45名65-83岁受试者随机接种含9 µg HA的0.3 mL MAS-1佐剂疫苗(15人)或高剂量IIV(15人),随后随机接种含9 µg HA的0.5 mL MAS-1佐剂疫苗(10人)或高剂量IIV(5人)。
- MAS-1佐剂剂量为0.3 mL或0.5 mL,含9 µg HA,HA来源于许可的季节性三价流感疫苗(IIV,Fluzone HD 60 µg HA,Sanofi Pasteur);对照为高剂量IIV(Fluzone HD)。
- 安全性通过反应原性、不良事件和安全性实验室指标评估;免疫原性通过血清血凝抑制(HAI)抗体滴度评估。
主要发现
- 注射部位压痛、硬结和疼痛,以及头痛、肌痛、不适和疲劳常见,在接种后第14天前消退。
- 0.5 mL佐剂剂量组10名受试者中有4名出现具有临床意义的迟发性注射部位反应。
- 安全性实验室指标在可接受范围内。
- MAS-1佐剂IIV增强针对疫苗株的平均抗体滴度、抗体滴度平均倍数增长和血清转化率,持续至少接种后168天,并增强对部分非研究疫苗流感病毒的交叉反应抗体。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased influenza vaccine efficacy is needed in the elderly at high-risk for morbidity and mortality due to influenza infection. Adjuvants may allow hemagglutinin (HA) dose-sparing with enhanced immunogenicity. MAS-1 is an investigational water-in-oil emulsion-based adjuvant/delivery system comprised of stable nanoglobular aqueous droplets. METHODS: A phase 1, randomized, double-blind, safety and immunogenicity, adjuvant dose escalation trial was conducted in persons aged 65 years and older. MAS-1 adjuvant dose volumes at 0.3 mL or 0.5 mL containing 9 µg per HA derived from licensed seasonal trivalent influenza vaccine (IIV, Fluzone HD 60 µg per HA, Sanofi Pasteur) were compared to high dose (HD) IIV (Fluzone HD). Safety was measured by reactogenicity, adverse events, and safety laboratory measures. Immunogenicity was assessed by serum hemagglutination inhibition (HAI) antibody titers. RESULTS: Forty-five subjects, aged 65-83 years, were randomly assigned to receive 9 µg per HA in 0.3 mL MAS-1 (15 subjects) or HD IIV (15 subjects) followed by groups randomly assigned to receive 9 µg per HA in 0.5 mL MAS-1 (10 subjects) or HD IIV (5 subjects). Injection site tenderness, induration, and pain, and headache, myalgia, malaise and fatigue were common, resolving before day 14 post-vaccination. Clinically significant late-onset injection site reactions occurred in four of ten subjects at the 0.5 mL adjuvant dose. Safety laboratory measures were within acceptable limits. MAS-1-adjuvanted IIV enhanced mean antibody titers, mean-fold increases in antibody titer, and seroconversion rates against vaccine strains for at least 168 days post-vaccination and enhanced cross-reactive antibodies against some non-study vaccine influenza viruses. CONCLUSION: MAS-1 adjuvant provided HA dose-sparing without safety concerns at the 0.3 mL dose, but the 0.5 mL dose caused late injection site reactions. MAS-1-adjuvanted IIV induced higher HAI antibody responses with prolonged durability including against historical strains, thereby providing greater potential vaccine efficacy in the elderly throughout an influenza season. Clinical Trial Registry: ClinicalTrials.gov # NCT02500680.
引用
- Gorse GJ, Grimes S, Buck H, et al. MAS-1, a novel water-in-oil adjuvant/delivery system, with reduced seasonal influenza vaccine hemagglutinin dose may enhance potency, durability and cross-reactivity of antibody responses in the elderly. Vaccine. 2022. PMID: 35125224. doi:10.1016/j.vaccine.2022.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。